Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug targets hidden heart risk in early trial

NCT ID NCT03626662

Disease control Sponsor: Amgen Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tested a single dose of an investigational drug called AMG 890 in 79 adults with high levels of lipoprotein(a), a genetic risk factor for heart disease. The main goal was to check safety and how the drug moves through the body. Researchers measured side effects and drug levels in the blood to prepare for future studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

79 people

The number who actually took part.

Started

Jul 2018

Finished

Apr 2023

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Men and women with ages between 18 and 70 years old, inclusive. * Protocol-defined elevated plasma Lp(a) level. * Body mass index (BMI) greater than or equal to 18 and less than or equal to 40 kg/m2, at screening. * Women must be of non-reproductive potential. * Other Inclusion criteria may apply Exclusion Criteria: * Currently receiving treatment in another investigational device or drug study. * Women who are lactating/breastfeeding or who plan to breastfeed while on study or through 90 days after receiving the last dose of investigational product (for subjects who withdraw prior to end of study). * History or evidence of a clinically significant disorder, condition or disease that would pose a risk to subject safety or interfere with the study evaluation, procedures or completion. * History or clinical evidence of bleeding diathesis or any coagulation disorder. * History or clinical evidence of peripheral neuropathy. * Other Exclusion criteria may apply

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiovascular disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cardiovascular disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiovascular disease

Contacts and locations

Locations

  • Clinical Medical and Analytical eXellence CMAX

    Adelaide, South Australia, 5000, Australia

  • Excel Medical Clinical Trials

    Boca Raton, Florida, 33434, United States

  • Jacksonville Center for Clinical Research

    Jacksonville, Florida, 32216, United States

  • Linear Clinical Research Limited

    Nedlands, Western Australia, 6009, Australia

  • Medpace Inc

    Cincinnati, Ohio, 45227, United States

  • New York University

    New York, New York, 10016, United States

  • Orange County Research Center

    Tustin, California, 92780, United States

  • QPS Miami Research Associates

    South Miami, Florida, 33143, United States

  • University of Kansas Medical Center

    Kansas City, Kansas, 66160, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.